The clinicopathological evaluation of the breast cancer patients with brain metastases: Predictors of survival

Clinical and Experimental Metastasis

Volumn 30, Issue 2, 2013, Pages 201-213

  Tarhan, Mustafa Oktay ^a   Demir, Lutfiye ^a   Somali, Isil ^b   Yigit, Seyran ^a   Erten, Cigdem ^a   Alacacioglu, Ahmet ^a   Ellidokuz, Hulya ^b   Seseogullari, Ozgur ^a   Kucukzeybek, Yuksel ^a   Can, Alper ^a   Dirican, Ahmet ^a   Bayoglu, Vedat ^a   Akyol, Murat ^a  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Brain metastases; Breast cancer; Clinical outcome; Tumor subtypes

Indexed keywords

ANASTROZOLE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LAPATINIB; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; DRUG DOSE REDUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SKIN METASTASIS; BRAIN TUMOR; BREAST TUMOR; CANCER GRADING; CANCER INVASION; ENZYME IMMUNOASSAY; FOLLOW UP; LIVER TUMOR; LUNG CARCINOMA; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SKIN TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

MLCS; MLOWN;

EID: 84875067375     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9528-7     Document Type: Article

References (43)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865
3. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Cancer 52(12):2349
4. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13(6):1648
5. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638
6. Yerushalmi R, Woods R, Kennecke H, Speers C, Knowling M, Gelmon K (2010) Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat 120(3):753
7. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14):4834
8. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112(11):2359
9. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM (2009) Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621
10. AJCC (2010) Cancer staging manual, 7th edn. Springer, Chicago
11. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer:I. The value of histologic grade in breast cancer:expreience from a large study with long-term follow-up. Histopathology 19:403-410
12. Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:966-978
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
14. Boogerd W (1996) Central nervous system metastasis in breast cancer. Radiother Oncol 40:5-22
15. Lee SS, Ahn J, Kim MK, Sym SJ, Gong G, Ahn SD, Kim S, Kim WK (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111:523-530
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752
17. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
18. Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 5:531-542
19. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang J-H, Ahn JS, Im Y-H (2010) Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 66:507-516
20. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114
21. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer. Oncologist 8:307-325
22. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crino L (2007) Central nervous system metastases in HER2-positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12:766-773
23. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261-2267
24. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549
25. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P (2006) The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66:2202-2209
26. Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942-948
27. Niwinska A, Olszewski W, Murawska M, Pogoda K (2011) Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. J Neurooncol 105:547-553
28. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. doi: 10.1002/cncr.27434
29. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107(4):696-704
30. Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Choi YJ, Cho GJ, Kim YS, Lee M, Lee JH, Kim DC, Lee HS, Cho SH, Kim HJ (2010) Clinical outcomes and breast cancer subtypes in patients with brain metastases. Onkologie 33(4):146-152
31. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45(16):2792-2798
32. Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106(3):440-446
33. Harputluoglu H, Dizdar O, Aksoy S, Kilickap S, Dede DS, Ozisik Y, Guler N, Barista I, Gullu I, Hayran M, Selek U, Cengiz M, Zorlu F, Tekuzman G, Altundag K (2008) Charactersitics of breast cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc 100(5):521-526
34. Kim HJ, Im SA, Keam B, Kim Y-J, Han S-W, Kim TM, Oh D-Y, Kim JH, Lee S-H, Chie EK, Han W, Kim D-W, Kim T-Y, Noh D-Y, Heo DS, Park IA, Bang Y-J, Ha SW (2012) Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol 106:303-313
35. Altaha R, Crowell E, Hobbs G, Higa G, Abraham J (2005) Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 103:442-443
36. Pinder M, Chang HY, Broglio KM et al. (2007) Trastuzumab treatment and brain metastases in HER2-positive metastatic breast cancer. In Poster 1018 Presented at the 43rd ASCO Annual Meeting, Chicago, (Abstr 1018)
37. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219-225
38. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O'Brien ME, Smith IE (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196-201
39. Yardley DA, Kaufman PA, Mayer M, et al. (2007) RegistHER: patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. In Poster 6049 Presented at the 30 th Annual San Antonio Breast Cancer Symposium, San Antonio, (Abstr 6049)
40. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P (2005) Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16:1772-1777
41. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in HER2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13:739-750
42. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee J-I, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im Y-H (2009) Trastuzumab treatment improves brain metastases outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100(6):894-900
43. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA (2011) The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117(8):1602-1611